Clinical-stage cell therapy
Advancing next-generation T-cell therapies for difficult-to-treat solid tumors.
CuraCell is a clinical-stage biotechnology company developing tumor-infiltrating lymphocyte (TIL) therapies powered by its proprietary CytoPLY™ T-cell activation and enrichment platform.
CC-38 · Phase I/IIa · Metastatic colorectal + prostate cancer
This is CuraCell
CuraCell develops cell-based immunotherapies for cancer treatment focusing on TILs (Tumor Infiltrating Lymphocytes), an investigational therapy aimed at a durable cure for solid tumor cancers.
The company is initiating its first clinical program targeting indications with high prevalence and the potential to make a significant impact for cancer patients worldwide.
CuraCell’s science
CuraCell advanced activation and enrichment platform, CytoPLY™ amplifies cytotoxicity of T-cell therapies such as TILs and TCR-Ts. CytoPLY™ enables T-cell therapies to advance into cold solid tumor cancers with large unmet medical needs. Applicable to a broad range of solid tumors, CuraCell’s first TIL product generation aims at late-stage prostate cancer and colorectal cancer.
Promising results from patient-named treatments lay a strong foundation for CuraCell’s next clinical step.
Our resources
CuraCell is committed to advancing cancer therapy through innovative research, strong partnerships, and global collaborations.
By utilizing our advanced facilities, we strive to develop impactful solutions that bring better treatments to patients with solid cancer.
-
R&D Lab
Cancer Center Karolinska, Solna
-
GMP Partnership
Zellwerk GmbH, Germany
-
R&D Collaborators
Karolinska Institutet & academic partners
Market opportunity
CuraCell is tackling the urgent need for effective treatments for solid tumor cancer, which impact millions of patients worldwide.
Discover how we can collaborate to advance cell therapy and make a meaningful difference for cancer patients.
